Glycoengineered chimeric IgG1 anti‑CD20 monoclonal antibody (brand: BRIUMVI) that depletes CD20+ B cells primarily via enhanced antibody‑dependent cellular cytotoxicity, and also through complement‑dependent cytotoxicity and apoptosis; used in relapsing multiple sclerosis.
Glycoengineered chimeric IgG1 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ B cells primarily via enhanced antibody‑dependent cellular cytotoxicity, and additionally through complement‑dependent cytotoxicity and apoptosis.
YES
DIRECT
Anti-CD20 IgG1 binds CD20 on B cells and eliminates them via Fc-mediated ADCC by effector cells, complement-dependent cytotoxicity, and induction of apoptosis.
Investigational adoptive cellular immunotherapy given as a single IV infusion (2.0×10^8 to 6.0×10^9 cells); BGT007H cells are intended to recognize a predefined tumor-associated antigen and mediate antigen-directed cytotoxicity against target-expressing tumor cells via cytotoxic lymphocyte mechanisms.
Adoptive transfer of genetically engineered cytotoxic lymphocytes that recognize a predefined tumor-associated antigen on tumor cells and induce antigen-directed killing via perforin/granzyme-mediated cytolysis and cytokine-driven immune activation.
YES
DIRECT
Engineered cytotoxic lymphocytes recognize the tumor-associated antigen and kill target cells via immune synapse formation and perforin/granzyme-mediated cytolysis (with cytokine-driven cytotoxicity).
Chimeric type I anti-CD20 monoclonal antibody that depletes CD20+ B cells primarily via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).
Chimeric type I anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them primarily via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), leading to elimination of CD20+ B cells.
YES
DIRECT
After binding CD20, rituximab triggers complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (NK cells/macrophages), leading to lysis and clearance of CD20+ B cells.
Humanized, glycoengineered type II anti-CD20 monoclonal antibody with enhanced FcγRIIIa binding, promoting stronger ADCC and direct cell death, leading to deeper and more sustained B-cell depletion.
Humanized, glycoengineered type II anti-CD20 IgG1 that binds CD20 on B cells and, through enhanced Fc-gamma receptor IIIa engagement, mediates strong antibody-dependent cellular cytotoxicity and phagocytosis and induces direct, caspase-independent cell death, leading to deep and sustained depletion of CD20+ B cells.
YES
DIRECT
Obinutuzumab binds CD20 on B cells, triggering direct caspase‑independent cell death and engaging Fc-gamma RIIIa on effector cells to mediate ADCC and antibody-dependent phagocytosis.
DLL3×CD3 bispecific T-cell engager antibody immunotherapy (also known as obrixtamig) that binds DLL3 on tumor cells and CD3 on T cells to activate cytotoxic T-cell killing.
A DLL3xCD3 bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells, activating and redirecting cytotoxic T cells to form immune synapses and kill DLL3-expressing cancer cells.
YES
DIRECT
The DLL3×CD3 bispecific antibody bridges CD3+ T cells to DLL3+ cells, forming immune synapses and triggering T‑cell cytotoxicity (perforin/granzyme-mediated lysis) of DLL3-expressing cells.